Exploration of Pyrido[3,4- d ]pyrimidines as Antagonists of the Human Chemokine Receptor CXCR2.
Molecules (Basel, Switzerland)(2023)
Abstract
Upregulated CXCR2 signalling is found in numerous inflammatory, autoimmune and neurodegenerative diseases, as well as in cancer. Consequently, CXCR2 antagonism is a promising therapeutic strategy for treatment of these disorders. We previously identified, via scaffold hopping, a pyrido[3,4-]pyrimidine analogue as a promising CXCR2 antagonist with an IC value of 0.11 µM in a kinetic fluorescence-based calcium mobilization assay. This study aims at exploring the structure-activity relationship (SAR) and improving the CXCR2 antagonistic potency of this pyrido[3,4-]pyrimidine via systematic structural modifications of the substitution pattern. Almost all new analogues completely lacked the CXCR2 antagonism, the exception being a 6-furanyl-pyrido[3,4-]pyrimidine analogue (compound ) that is endowed with similar antagonistic potency as the original hit.
MoreTranslated text
Key words
CXCR2 antagonists,SAR study,pyrido[3,4-d]pyrimidines
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined